Italy considers legal action over Pfizer vaccine delivery delays
By Emilio Parodi and Stephen Jewkes ROME (Reuters) - Italy is considering legal action against Pfizer Inc after the U.S. drugmaker announced a further cut in coronavirus vaccine deliveries, the country's COVID-19 special commissioner Domenico Arcuri said
By Emilio Parodi and Stephen Jewkes
ROME (Reuters) - Italy is considering legal action against Pfizer Inc after the U.S. drugmaker announced a further cut in coronavirus vaccine deliveries, the country's COVID-19 special commissioner Domenico Arcuri said.
Pfizer is facing criticism across Europe over its surprise move to temporarily delay vaccine shipments to countries that fear disruptions could throw their inoculation campaigns into disarray.
The company told Italy last week that it was cutting its deliveries by 29%. On Tuesday, it said it was not in the position to make up the 29% shortfall next week and that it was planning a further "slight reduction" in deliveries, Arcuri said.
"As a result, we discussed what action to take to protect Italian citizens and their health in all civil and criminal venues," Arcuri said in a statement late on Tuesday.
"It was unanimously decided that these actions will be taken starting in the next few days."
He did not elaborate.
The Pfizer vaccine requires two injections, given around 21 days apart, to prime the immune system well enough to fight off the coronavirus .
Pfizer's move was having a serious impact on vaccination plans drawn up by local authorities, the governor of the northern Emilia Romagna region said.
"Due to the reduction in doses, many regions have been forced to slow down or even suspend new vaccinations to ensure administration of the second dose to those who had already received the first," Stefano Bonaccini told Reuters in an email.
A spokeswoman for Pfizer declined to comment on Wednesday over Italy's legal threat and criticism regarding delivery delays beyond its statement on Friday about supply cuts.
The drugmaker said last week it was temporarily slowing supplies of its coronavirus vaccine to Europe to make manufacturing changes that would boost output.
Pfizer, which is trying to deliver millions of doses at a breakneck pace to curb a pandemic that has already killed more than 2 million people worldwide, said the changes would "provide a significant increase in doses in late February and March".
According to an Italian source, Rome is now trying to assess whether Pfizer is acting under force majeure, or circumstances beyond its control.
If not, the drug group could be accused of breaching the contract it has signed with the European Union on state members' behalf, the source said.
One possibility could be for Rome to call on the European Union to present a lawsuit to a court in Belgium's capital, Brussels, the source said.
"Regional authorities will stand by the government in any necessary action but I sincerely hope this eventuality will not occur," Bonaccini said.
(Reporting by Emilio Parodi and Stephen Jewkes in Milan, Domenico Lusi in Rome; additional reporting by Josephine Mason in London; Writing by Giselda Vagnoni; Editing by Nick Macfie)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply
By Christoph Steitz, Tom Käckenhoff and Arno Schuetze FRANKFURT (Reuters) - German conglomerate Thyssenkrupp ended talks to sell its steel division to Britain's Liberty Steel due to differences over value, the latest setback in efforts to consolidate the European sector. Liberty Steel, led by commodities tycoon Sanjeev Gupta, last month submitted a firmed-up non-binding bid for Thyssenkrupp's steel unit, Europe's second biggest in terms of sales, which sources said included commitments to protect jobs and sites.
(Reuters) - Reddit trading lingo may filter in to Washington on Thursday when top hedge fund managers, the head of Robinhood and Roaring Kitty himself are set to give testimony before U.S. House of Representatives lawmakers.
By Stephanie Kelly NEW YORK (Reuters) - Oil prices steadied on Thursday, with Brent edging back from a 13-month high, after a sharp drop in U.S. crude inventories supported prices, while buying spurred by a cold snap in the largest U.S. energy-producing state petered out.